Table 3 Clinical characteristics and inflammation parameters of patients with type 2 diabetes mellitus before and after glycemic optimization (n = 42)
Baseline | After glycemic optimization | |
|---|---|---|
Male/female | 27/15 | - |
Age (years) | 61 ± 12 | - |
Diabetes duration (years) | 37 ± 14 | - |
Chronic complications: | ||
● Retinopathy (%) | 59 | - |
● Nephropathy (%) | 51.3 | - |
● Coronary Heart Disease (%) | 17.9 | - |
Insulin use (%) | 75 | 85.7 |
Cholesterol lowering medication (%) | 59.5 | 59.5 |
Weight (kg) | 80.35 ± 19.52 | 80.02 ± 19.71 |
Body mass index (Kg/m2) | 29.0 ± 5.8 | 28.8 ± 6 |
HbA1c (%) | 9.5 ± 1.8 | 7.4 ± 0.8* |
C-reactive protein (mg/l) | 3.20 ± 2.86 | 3.15 ± 3.26 |
Interleukin-6 (ng/l) | 1.49 ± 1.12 | 1.29 ± 0.70 |
Interleukin-8 (ng/l) | 12.84 ± 7.57 | 13.82 ± 10.35 |
Transforming growth factor β1 (ng/l) | 41.86 ± 32.84 | 26.64 ± 26.91* |
Monocyte chemotactic protein 1 (ng/l) | 224.31 ± 76.03 | 227.48 ± 132.79 |
Leptin (ng/l) | 7594 ± 8852 | 7817 ± 7295 |
Adiponectin (ng/l) | 3673 ± 3455 | 4084 ± 3927 |